Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1983

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

NORPLANT subdermal implants approved by Finland: worldwide effort to

introduce new contraceptive begins [news release]

AUTHORS

Population Council

SOURCE

[Unpublished] 1983 Nov 23. 2 p.

ABSTRACT

The Finnish National Board of Health has approved the sale and distribution in Finland of Norplant subdermal

implants. The Norplant contraceptive method was developed by the Population Council. Norplant implants will be

manufactured by Huhtamaki Oy, Leiras Pharmaceuticals, an international pharmaceutical firm based in Finland,

under license from the Population Council. Distribution will begin immediately in Finland, and registration will be

initiated in over 40 additional countries, including the US, during the next 3-4 years. The implants have been tested

in clinical studies and field trials involving more then 7000 women in 14 countries. They have been found to be the

most effective contraceptive yet developed, with a pregnancy rate of less then 0.5/100 woman-years of exposure. The

contraceptive effect is achieved within 24 hours of insertion and lasts for 5 years. As the Norplant implants become

more widely available, they are expected to make a substantial contribution to international family planning programs.

(PubHealth.info Document ID: CONT5T 2045-06)

PubHealth.info NOTE: The author(s) of this article titled, "NORPLANT subdermal implants approved by Finland:

worldwide effort to introduce new contraceptive begins [news release]", is(are) Population Council. The source of

this article is "[Unpublished] 1983 Nov 23. 2 p.". This article was published in 1983 in English language(s).

(PubHealth.info® Document ID: CONT5T 2045-06. All rights reserved with PubHealth.info) PIN: 22045

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.